4 completed, 1 terminated. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Terminated 1 |
| Phase 2 | 2 | Completed 2 |
Follow Farxiga: new trials by email Literature Review of Farxiga trials Research Report on Farxiga
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer Dapagliflozin - Prostate Cancer, Cancer of Prostate | Phase 1 | Terminated | Washington University School of Medicine | 5 | 2024-06-04 | 2026-06-30 |
| Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition Dapagliflozin, BIOSENSE meters - Pancreas Cancer, Pancreatic Cancer | Phase 1 | Completed | Washington University School of Medicine | 15 | 2021-02-25 | 2023-02-14 |
| SGLT2 Inhibition in Older Obese Adults With Pre-diabetes Dapagliflozin 10 mg, Nutritional counseling - Aging | Phase 1 / Phase 2 | Completed | The University of Texas Health Science Center at San Antonio | 20 | 2020-06-25 | 2024-01-05 |
| Dapagliflozin In Alzheimer's Disease Dapagliflozin, Placebo - Alzheimer Disease | Phase 1 / Phase 2 | Completed | Jeff Burns, MD | 46 | 2019-01-29 | 2024-06-13 |
| Dapagliflozin Effects on Hypoglycemia Dapagliflozin 5mg, Placebo Oral Tablet - Type1 Diabetes Mellitus | Phase 1 | Completed | University of California, San Diego | 22 | 2018-10-08 | 2024-01-23 |
Alzheimer Disease (1) · Glucose Intolerance (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1)
Washington University School of Medicine (2) · Jeff Burns, MD (1) · The University of Texas Health Science Center at San Antonio (1) · University of California, San Diego (1)
United States (5)
Carolina Solis-Herrera (1) · Jeffrey Burns, MD (1) · Kian-Huat Lim, M.D. (1) · Melissa A Reimers, M.D. (1)
PMID 34857545, PMID 37202813, PMID 39168098
P30AG044271 (1), P50CA196510 (1)